Therapeutic agent for cancer which comprises combination of IL-18 and molecule-targeting antibody

摘要

A therapeutic agent for cancer according to the present invention contains, as active ingredients, IL-18 and at least one antibody selected from the group consisting of an anti-PD-L1 antibody, an anti-PD-1 antibody, an anti-PD-L2 antibody, an anti-CTLA-4 antibody, an anti-CD25 antibody, an anti-CD33 antibody and an anti-CD52 antibody.